Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft– – The observed synergy emphasizes...

Related Keywords

United States ,American ,Sheila Connelly ,Theriva Biologics ,Stevena Shallcross ,Chris Calabrese ,Lifesci Advisors ,Biologics Inc ,Company Annual Report On Form ,Globenewswire Inc ,American Society For Cell ,Theriva Biologics Inc ,Gene Therapy ,Annual Meeting ,Chief Executive Officer ,Enhanced Anti Tumor Efficacy ,Combination Therapy ,Oncolytic Adenovirus ,Liposomal Irinotecan ,Human Pancreatic Mouse ,Vice President ,Session Date ,Theriva Biologic ,Private Securities Litigation Reform Act ,Annual Report ,Sci Advisors ,Markets ,